HEMATOPOIESIS AND STEM CELLS

miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling

Tushar D. Bhagat,1 Li Zhou,1 Lubomir Sokol,2 Rachel Kessel,1 Gisela Caceres,2 Krishna Gundabolu,1 Roni Tamari,1 Shanisha Gordon,1 Ioannis Mantzaris,1 Tomasz Jodlowski,1 Yiting Yu,1 Xiaohong Jing,1 Rahul Polineni,1 Kavi Bhatia,1 Andrea Pellagati,3 Jacqueline Boulwood,3 Suman Kambhampati,4 Ulrich Steidl,1 Cy Stein,1 Wenjun Ju,5 Gang Liu,6 Paraic Kenny,1 Alan List,2 Markus Bitzer,1,5 and Amit Verma1

1Albert Einstein College of Medicine, Bronx, NY; 2Moffitt Cancer Center, Tampa, FL; 3LLR Molecular Haematology Unit, NDCLS, John Radcliffe Hospital, Oxford, UK; 4VA Medical Center/University of Kansas Medical Center, Kansas City, MO; 5University of Michigan, Ann Arbor, MI; and 6University of Alabama, Birmingham, AL

Key Points

• We observed that SMAD7, a negative regulator of TGF-β receptor-I kinase, is markedly reduced in MDS, and leads to ineffective hematopoiesis.
• Increased levels of microRNA-21 are seen in MDS and reduce SMAD7 expression, thus overactivating TGF-β signaling.

Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis that leads to peripheral cytopenias. We observed that SMAD7, a negative regulator of transforming growth factor-beta (TGF-β) receptor-I kinase, is markedly reduced in MDS and leads to ineffective hematopoiesis by overactivation of TGF-β signaling. To determine the cause of SMAD7 reduction in MDS, we analyzed the 3’UTR of the gene and determined that it contains a highly conserved putative binding site for microRNA-21. We observed significantly elevated levels of miR-21 in MDS marrow samples when compared with age-matched controls. miR-21 was shown to directly bind to the 3’UTR of SMAD7 and reduce its expression in hematopoietic cells. Next, we tested the role of miR-21 in regulating TGF-β signaling in a TGF-β-overexpressing transgenic mouse model that develops progressive anemia and dysplasia and thus serves as a model of human bone marrow failure. Treatment with a chemically modified miR-21 inhibitor led to significant increases in hematocrit and led to an increase in SMAD7 expression in vivo. Inhibition of miR-21 also led to an increase in erythroid colony formation from primary MDS bone marrow progenitors, demonstrating its ability in stimulating hematopoiesis in vitro. Taken together, these studies demonstrate the role of miR-21 in regulating overactivated TGF-β signaling in MDS. (Blood. 2013;121(15):2875-2881)

Introduction

The myelodysplastic syndromes (MDS) are clonal stem cell disorders characterized by cytologic dysplasia and ineffective hematopoiesis.1-3 Although approximately one-third of patients’ disease may progress to acute leukemia, refractory cytopenias are the principal cause of morbidity and mortality in patients with MDS.4 In fact, approximately two-thirds of patients present with lower-risk disease characterized by hypercellular marrows, with increased rates of apoptosis in the progenitor and differentiated cell compartments in the marrow.5-8 Ineffective hematopoiesis arising from abortive maturation leads to peripheral cytopenias. Higher grade or more advanced disease categories are associated with a significant risk of leukemia transformation with a corresponding lower apoptotic index and higher percentage of marrow blasts.

Cytokines play important roles in the regulation of normal hematopoiesis, and a balance between the actions of hematopoietic growth factors and myelosuppressive factors is required for optimal production of different hematopoietic cell lineages. Excess production of inhibitory cytokines amplifies ineffective hematopoiesis inherent to the MDS clone. Transforming growth factor-beta (TGF-β) is a myelosuppressive cytokine that has been implicated in the hematopoietic suppression in MDS. The plasma levels of TGF-β have been reported to be elevated in some6-13 but not all studies14-17 and are supported by greater TGF-β immunohistochemical staining in selected studies. Conflicting data may arise from technical limitations of bone marrow immunohistochemical analyses of a secreted protein, as well as the biological heterogeneity of the disease itself. Thus, we investigated the role of TGF-β in MDS by direct examination of receptor signal activation to conclusively determine its role in the pathogenesis of ineffective hematopoiesis in MDS. We determined that the SMAD2 is upregulated and overactivated in MDS bone marrow progenitors, thereby demonstrating sustained TGF-β signal activation in this disease. Because there is conflicting data about upregulation of extracellular TGF-β levels in MDS, we next sought to determine the molecular basis of TGF-β receptor-I overactivation and subsequent SMAD2 phosphorylation/activation in this disease. We observed that SMAD7, a negative regulator of TGF-β receptor-I...
kinase, is markedly decreased in MDS and this leads to overactivation of TGF-β signal transduction, even in the absence of increased levels of extracellular TGF-β. Thus, we wanted to focus on the molecular alterations that lead to SMAD7 reduction in MDS. In the present study, we were able to show that miR-21 is increased in MDS, binds to the 3′UTR of the SMAD7 gene, and leads to consequent up-regulation of the TGF-β pathway in MDS. We were also able to show that inhibition of this microRNA is able to abrogate TGF-β signaling both in vitro and in vivo and stimulates hematopoiesis in MDS.

Materials and methods

Cells lines and reagents

Human CD34+ cells were isolated from the bone marrow of normal or MDS patients after obtaining informed consent in accordance with the Declaration of Helsinki and approval by the institutional review board of Albert Einstein College of Medicine. Bone marrow CD34+ cells from various normal donors were also obtained from AlCells (Emeryville, CA). HS-5 cell line (CRL-11882) was purchased from ATCC (Manassas, VA). TGF-β1 was bought from R&D Systems (Minneapolis, MN). The phos-MA1D2 (S465/467) and actin antibodies were from Cell Signaling Technology (Beverly, MA), and SMAD2 antibody was from Invitrogen (Carlsbad, CA), SMAD7 antibody was from ABcam (Cambridge, MA). Locked nucleic acid (LNA)-modified miR-21 inhibitor was provided by Exiqon (Woburn, MA).

Cell lysis and immunoblotting

Cells were lysed in phosphorylation lysis buffer as previously described. Immunoblotting was performed as previously described.

Gene expression analysis

Gene expression data were obtained from 183 MDS CD34+ cells and 17 controls. Clinical information for the cases was provided by the authors. SMAD7 and SMAD2 expression was represented as box plots using R statistical software.

qPCR for miR-21

Quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) was done for miR-21 and endogenous control, RNU44, on MDS and age-matched control bone marrow mononuclear cells (MNCs) after obtaining informed consent approved by the institutional review board of Moffitt Cancer Center. Reverse-transcriptase reactions and real-time PCR were performed on Applied Biosystems Real-Time PCR instruments (Applied Biosystems, Foster City, CA) according to the manufacturer’s protocols as described elsewhere.

Murine experiments

TGF-β1 transgenic mice expressing a fusion gene (Alb/TGF) consisting of modified porcine TGF-β1 cDNA under the control of the regulatory elements of the mouse albumin gene were used under animal institute–approved protocol. Mice were given LNA miR-21 inhibitors (Exiqon) at a dose of 25 mg/kg given intraperitoneally on alternate days for a total of 5 doses. Mis-matched oligos were used as controls at similar doses. Blood counts were analyzed by Advia machine (Siemens, Princeton, NJ).

SMAD7 gene reporter assay

HS-5 cells were plated in 6-well plates 24 hours before transfection. Cells were transfected in triplicate with SuperFect (Qiagen, Alameda, CA) according to the manufacturer’s instructions. To generate SMAD7 3′UTR mutants containing mutations in the conserved miR-21 binding site, site-directed mutagenesis was performed using the wild-type 3′UTR as the template. In the 3′UTR mutant, the nucleotide sequence complementary to nt 2–5 of miR-21 was mutated to the same sequence as that in miR-21 (from AGCT to TCGA). Luciferase reporters containing wild-type and mutant 3′UTR of SMAD7 gene were used for transfection with Pre-miR miR-21 precursors (Ambion, Inventrogen) or controls (30 nM). The generation of wild-type and mutant constructs has been described previously. Cells were harvested 24 hours later in reporter lysis buffer, and luciferase and renilla activities were determined using Dual Luciferase System (Promega, Madison, WI).

miR-21 overexpression

A plasmid-encoding miR-21 and green fluorescent protein (GFP) in the pMIF-cGFP-Zeo lentiviral vector (Systems Biosciences, Mountain View, CA) was introduced into cells by nucleofection. The empty pMIF-cGFP-Zeo vector, encoding only GFP, was used as a negative control.

Hematopoietic progenitor cell assays

Hematopoietic progenitor colony formation was determined by clonogenic assays in methylcellulose, as in our previous studies. All participants in the study signed informed consent, approved by the institutional review board of Albert Einstein College of Medicine. Granulocyte/macrophage colony-forming units (CFU-GM) and erythroid burst-forming units (BFU-E) from bone marrow samples were scored on day 14 of the culture.
Fluorescence in situ hybridization

After 14 days of methylcellulose culture, cells were isolated from the plates and cytospun on microscopic slides. The cells on the slides were fixed in Carnoy’s solution. The following dual color probes (Abbott Molecular, Abbott Park, IL) were used to detect 7q deletions and 5q deletions: LSI D7S522 (7q31) SpectrumOrange/CEP7 SpectrumGreen, EGR-1 SpectrumOrange/D5S721/D5S23 SpectrumGreen. Fluorescence in situ hybridization was performed according to the manufacturer’s instructions. Cells were counterstained with 4′,6-diamidino-2-phenylindole and examined on a Zeiss Axioplan 2 fluorescence microscope (Zeiss, North Chesterfield, VA).

Results

SMAD7 is reduced in bone marrow progenitors in MDS

SMAD7 is a negative regulator of the TGF-β signaling pathway and inhibits the activity of the TGF-β receptor-I kinase. We analyzed the expression of SMAD7 in a large gene expression dataset obtained from bone marrow CD34+ selected samples from MDS patients. We found that SMAD7 is significantly reduced in

---

Figure 2. miR-21 has a putative binding site on the SMAD7 3′ UTR and is overexpressed in MDS. (A) Targetscan software predicts a strong possibility of miR-21 binding site at position 1122 of the SMAD7 3′ UTR with a highly conserved site. (B) Microarray analysis of 41 untreated MDS marrow samples were compared with 10 age-matched controls and demonstrate upregulation of miR-21 (mean intensity ± SEM, Student’s t-test, $P = .001$). (C) Quantitative RT-PCR was done for miR-21 and endogenous control, RNU44, on 19 MDS and 13 age-matched control bone marrow MNCs using the Ambion Taqman microRNA assay kit. MDS samples had significantly higher expression of miR-21 (*Student’s t-test, $P = .04$). Both lower- and higher-risk MDS (low-risk MDS, $N = 10$, $P$ value = .04; high-risk MDS, $N = 9$, $P = .03$, Student’s t-test) had higher mean expression when compared with controls.

Figure 3. miR-21 binds to SMAD7 3′ UTR. (A) The nucleotide sequence complementary to nt 2–5 of miR-21 in the 3′ UTR of SMAD7 was mutated to the same sequence as that in miR-21 (from AGCT to TCGA). (B) Luciferase reporters containing wild-type and mutant 3′ UTR of the SMAD7 gene were used for transfection with control miRNA or miR-21 precursors into bone marrow stromal HS-5 cells. Dual luciferase activity was measured and shows decreased luciferase activity caused by miR-21 that is abrogated by mutation in its binding site on the UTR (Student’s t-test, $P = .001$) compared with cells transfected with control mimics.
these samples when compared with healthy controls (Figure 1, mean log2 expression 8.31 in controls vs 6.32 in MDS samples, false discovery rate < 0.1, Benjamin Hochberg correction multiple testing, Student’s t-test < 0.001). Furthermore, SMAD2, the effector SMAD protein for TGF-β signaling was found to be increased in the same samples (Figure 1B, mean log2 expression 8.4 in controls vs 8.8 in MDS samples, false discovery rate < 0.1, Benjamin Hochberg correction multiple testing, Student’s t-test < 0.001), demonstrating the sustained activation of TGF-β pathway in these samples. Subset analysis revealed striking increase in SMAD2 reduction in all subsets of MDS examined (Figure 1A). Correlation of SMAD7 levels with clinical parameters did not reveal any association with age, sex, or cytogenetics, revealing it to be a pervasive gene.

miR-21 binding directly to 3'UTR of SMAD7, reduces the expression of SMAD7, and inhibits erythroid colony formation

We next wanted to determine whether miR-21 expression can decrease SMAD7 expression and whether this effect is caused by direct interaction of miR-21 with the SMAD7 3'UTR. A luciferase reporter containing the 3'UTR segment containing predicted microRNA interaction sites was used to analyze the interaction between miR-21 and SMAD7.
effect of miR-21 on *SMAD7* gene transcription in bone marrow stromal HS-5 cells. The nucleotide sequence complementary to nts 2–5 of miR-21 binding site in the 3' UTR of *SMAD7* was mutated to the same sequence as that in miR-21 (from AGCT to TCGA) (Figure 3A). Dual luciferase activity was measured and showed decreased *SMAD7* luciferase activity caused by expression of miR-21 compared with cells transfected with control mimics. This was abrogated by mutation in its binding site on the UTR (Student’s *t*-test, *P* < 0.001), demonstrating a direct effect of miR-21 on the 3' UTR of *SMAD7* (Figure 3A).

Subsequently, the effect of miR-21 on *SMAD7* expression was tested by using a chemically modified LNA inhibitor that led to decreased levels of miR-21 transcripts (Figure 4A) when compared with mismatched control. We observed that inhibition of miR-21 led to an increase in *SMAD7* protein expression in leukemic cell lines and in primary MDS patient samples (Figure 4B). Inhibition of miR-21 also led to decreased phosphorylation/activation of *SMAD2* in a MDS patient sample (Figure 4C). Next, we tested the functional role of miR-21 in regulating the effects of TGF-β on normal hematopoiesis and the role of *SMAD7* in regulating these effects. CD34+ cells were transfected with shRNAs against *SMAD7* and controls as performed previously, sorted for GFP expression, and then treated with TGF-β in the presence and absence of the miR-21 inhibitor. We observed that miR-21 inhibition was able to abrogate the inhibitory responses of TGF-β on erythroid colony formation from primary human CD34+ stem cells that were transfected with scrambled control shRNAs (Figure 4D). This effect was not seen in cells transfected with shRNAs against *SMAD7*.

Furthermore, we also overexpressed miR-21 in separate experiments by using lentiviral vector-encoding miR-21 precursors (pMIF-cGFP-Zeo), along with a control vector that expressed only GFP. Overexpression of miR-21 led to decreased *SMAD7* protein levels in leukemic cells (Figure 4E) and led to quantitative and qualitative reduction in erythroid colony formation from primary CD34+ cells (Figure 4F-G). Taken together, these data demonstrate that miR-21 potentiates TGF-β signaling in hematopoietic cells via down-regulation of *SMAD7*.

![Figure 5](http://example.com/figure5.png)

Figure 5. Treatment with mir21 inhibitor leads to an increase in red blood cells in TGF-β transgenic mice. (A) Mice expressing TGF-β (Alb/TGFβ+) were treated with LNA-modified anti–miR-21 (n = 7) or mismatched placebo controls (n = 6) for 5 doses. Mice treated with anti–miR-21 oligos had a significant increase in hematocrit (HCT, Student’s *t*-test, *P* = .03), hemoglobin (Hgb [gm/DL], Student’s *t*-test, *P* = .049), and red blood cells (RBCs [x10⁶]). Student’s *t*-test, *P* = .0005. (B) Equal numbers of bone marrow cells were grown in methylcellulose and demonstrated increased erythroid colony formation in the mice treated with miR-21 inhibitor (n = 5 in each group, Student’s *t*-test, *P* = .04). (C) Representative bone marrow biopsy samples from both groups show an increase in *SMAD7* levels in the treatment group with a corresponding decrease in phospho-SMAD2.

---

**Table 1. MDS patient characteristics and response to miR-21 inhibition**

<table>
<thead>
<tr>
<th>N</th>
<th>Age/Sex</th>
<th>WBC (10⁹/mL)</th>
<th>Hgb (g/dL)</th>
<th>Plt (10⁹/mL)</th>
<th>Subtype</th>
<th>Cytogenetics</th>
<th>Colonies post treatment with mismatched control</th>
<th>Colonies post treatment with miR-21 inhibitor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BFU-E</td>
<td>CFU-GM</td>
</tr>
<tr>
<td>1</td>
<td>63/M</td>
<td>1.2</td>
<td>9</td>
<td>14</td>
<td>RCMRD</td>
<td>+11</td>
<td>204</td>
<td>12</td>
</tr>
<tr>
<td>2</td>
<td>79/F</td>
<td>2.9</td>
<td>9.6</td>
<td>29</td>
<td>RAEB</td>
<td>−7q</td>
<td>22</td>
<td>4</td>
</tr>
<tr>
<td>3</td>
<td>68/F</td>
<td>3.5</td>
<td>9.3</td>
<td>35</td>
<td>RAEB</td>
<td>−5q, −18</td>
<td>20</td>
<td>37</td>
</tr>
<tr>
<td>4</td>
<td>70/M</td>
<td>18.2</td>
<td>8.5</td>
<td>84</td>
<td>RAEB</td>
<td>Nml</td>
<td>91</td>
<td>93</td>
</tr>
<tr>
<td>5</td>
<td>69/F</td>
<td>5.2</td>
<td>8.8</td>
<td>75</td>
<td>RCMRD</td>
<td>Nml</td>
<td>62</td>
<td>26</td>
</tr>
</tbody>
</table>

WBC, white blood cells; plt, platelets; Hgb, hemoglobin.
Inhibition of miR-21 can improve anemia in a model of TGF-β–driven bone marrow failure

To test the role of miR-21 in regulating TGF-β signaling in vivo, we used chemically modified inhibitors of miR-21 and tested them in a transgenic mouse expressing a fusion gene (Alb/TGF) consisting of modified porcine TGF-β cDNA under the control of the regulatory elements of the mouse albumin gene. We have shown that these mice constitutively secrete TGF-β, become anemic, and have histologic marrow findings that mimic human MDS, thus serving as an in vivo model of bone marrow failure. These mice were randomized into a treatment or placebo group on the basis of pretreatment hematocrit levels. Blood counts were measured after administration of miR-21 inhibitor or control. miR-21 inhibitor treatment led to increased expression of SMAD7 and inhibition of constitutive SMAD2 activation in murine bone marrow (see Figure 5C). Mice treated with miR-21 inhibitor had a significant increase in hematocrit (Figure 5A) and were able to form more erythroid colonies from marrow-derived cells (Figure 5B) when compared with control (Student’s t-test, P < .05). These results demonstrate the role of miR-21 inhibition in inhibiting TGF-β signaling in vivo.

Inhibition of miR-21 can stimulate MDS hematopoiesis

Finally, we tested the ability of chemically modified (LNA) miR-21 inhibitor in vitro in 5 primary MDS bone marrow samples. These included different subtypes of MDS (Table 1). Mononuclear cells from the bone marrow were grown in methylcellulose with cytokines in the presence of miR-21 inhibitor and control. Treatment with the miR-21 inhibitor resulted in a significant increase in erythroid (BFU-E) colony numbers in all patients (results depicted as means in Figure 6A and Table 1). miR-21 inhibitor treatment did not result in any significant increase in colony formation from healthy controls (Figure 6B). Karyotypic analysis of colonies from 2 MDS samples revealed a reduction in percentage of cells with cytogenetic alterations in miR-21 inhibitor–treated cells when compared with controls (20% in treated vs 29% in controls for 5q deletion; 3% in treated vs 11% in controls for 7q deletion). In addition to confirming the findings from our studies in mice, these results point to the potential stimulatory effect of miR-21 inhibition on MDS hematopoiesis.

Discussion

The discovery of effective treatments for MDS has been challenged by the limited insight into molecular pathogenesis of the ineffective hematopoiesis seen in these disorders. Even though TGF-β levels have been shown to be elevated in a subset of MDS cases, our previous work has shown that intracellular signaling is activated in a large proportion of cases. Furthermore, we demonstrated that SMAD7 downregulation may be the key mechanism driving the suppression of hematopoiesis in MDS via overactivation of the TGF-SMAD2 pathway. This would also explain increased TGF-β signal transduction even in the absence of large amounts of circulating TGF-β that have been observed in various studies in MDS patients. In the present study, we determined the reasons for downregulation of SMAD7 in MDS and observed that miR-21 can bind to the 3’UTR region of the SMAD7 gene, reduce its expression, and potentiate TGF-β signaling in hematopoietic cells. Furthermore, inhibition of miR-21 can stimulate hematopoiesis in vitro and in vivo, thus demonstrating a critical role of this microRNA in regulation of myelosuppressive pathways in MDS.

SMAD7 is an important regulator of TGF-β signaling and its dysregulation has been implicated in many disease and cancer models. Genome-wide association studies have shown that polymorphisms in the SMAD7 gene are some of the most significant genetic alterations in colorectal cancer. A recent study showed that decreased SMAD7 is also seen in idiopathic pulmonary fibrosis and contributes to TGF-β–mediated fibrosis seen in this disease. Our study demonstrates that SMAD7 reduction is seen in a large number of MDS samples and points to its role in hematopoietic failure seen in this disease. The bone marrow at earlier stages of MDS is hypercellular and is characterized by ineffective hematopoiesis affecting both stem and progenitor cells. Because TGF-β is a critical regulator of hematopoiesis and affects both proliferation and differentiation of stem cells, an aberrant increase in TGF-β signaling can potentially explain the changes seen in MDS.

There could be many possible reasons for SMAD7 reduction in MDS. Even though the deletion of chromosome 18/18q, where the SMAD7 gene is located, was noticed to be a common deletion in MDS, it is only seen in a small proportion of patients with the disease. Furthermore, even though splicing mutations have recently been discovered in MDS, it is possible that splicing abnormalities can also affect SMAD7 transcripts, even though this information is not yet available. Because microRNAs are important regulators of genes, we decided to examine miR-mediated degradation of SMAD7 in MDS. We were able to show that miR-21 directly binds to the SMAD7 3’UTR region and regulated TGF-β signaling. miR-21 has been well studied in cancer and has been shown to influence a variety of targets including PTEN, PLAG1, and NFIB among others. A recent study demonstrated that miR-21–mediated degradation of SMAD7 was seen in pulmonary tissue and led to increased TGF-β–mediated fibrosis in idiopathic lung fibrosis. We show that this phenomenon can be seen in a hematologic disease and can explain the reduced SMAD7 levels seen in bone marrow progenitors. Our findings also raise the question of why miR-21 is found to be upregulated in MDS. In recent studies, the miR-21 gene locus has been shown to contain STAT3 binding sites. Furthermore, STAT3 has also been shown to directly lead to miR-21 upregulation in immune cells. Our genomic analysis of hematopoietic stem cells in MDS demonstrated that STAT3 is selectively upregulated in these cells. Thus, it is possible that this leads to miR-21 upregulation seen by us in MDS that in turn enhances TGF-β signaling that leads to ineffective hematopoiesis.
Most importantly, our results demonstrate that the activation of the TGF-β pathway by SMAD7 reduction in MDS can be abrogated by miR-21 inhibition both in vitro and in vivo. Ineffective hematopoiesis and anemia cause most of the morbidity in patients with MDS. Two-thirds of all MDS patients are at the low-risk stage of disease, have a lower chance of the disease progressing to leukemia, and have problems associated primarily with low red blood cell counts. Because TGF-β has been specifically shown to regulate both the early and late stages of erythropoiesis, miR-21 can be predicted to affect red cell production in particular, as was seen in the present study. Thus, taken together our findings support the exploration of miR-21 inhibitors in future preclinical and clinical studies in MDS.

Acknowledgments

This work was supported by a Leukemia and Lymphoma Society Translational Research grant, the American Cancer Society (RSG-09-037), the Gabrielle Angel foundation, the Immunology and Nephrology grant, the American Cancer Society (RSG-09-105-01-CPPB), and a Carl Gottschalk Research Scholarship awarded by the American Society of Nephrology.

References